CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany

Core Insights - CytoDyn Inc. is set to present promising survival data for leronlimab at the ESMO Breast Cancer meeting, highlighting its potential in treating metastatic triple-negative breast cancer (mTNBC) [1][2] Company Overview - CytoDyn is a clinical-stage biotechnology company focused on developing leronlimab, a humanized IgG4 monoclonal antibody targeting the CCR5 receptor, which is implicated in various disease processes [4] Clinical Development - A review of previous clinical trials indicated favorable survival rates at 12, 24, and 36 months for patients treated with leronlimab compared to existing therapies [2] - The company confirmed that some patients with mTNBC, who had undergone four prior treatment lines, are alive over 48 months post-treatment, with some showing no evidence of disease [2] Upcoming Presentation - Dr. Jacob Lalezari and Dr. Richard Pestell will present at the ESMO conference on May 15, 2025, discussing the clinical development of leronlimab and its potential mechanism of action in long-term survivors [3]